Jennifer Eads
Overview
Explore the profile of Jennifer Eads including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
251
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rajdev L, King G, Lieu C, Cohen S, Pant S, Uboha N, et al.
JCO Precis Oncol
. 2025 Mar;
9:e2400489.
PMID: 40048671
Purpose: Circulating tumor DNA (ctDNA) is an emerging tool in the evaluation of GI cancers. Challenges remain in defining its utility and role as a primary end point in therapeutic...
2.
Till J, McDaniel L, Chang C, Long Q, Pfeiffer S, Lyman J, et al.
Nat Commun
. 2024 Jul;
15(1):5763.
PMID: 38982051
While high circulating tumor DNA (ctDNA) levels are associated with poor survival for multiple cancers, variant-specific differences in the association of ctDNA levels and survival have not been examined. Here...
3.
Li Y, Wu S, Zhao Y, Dinh T, Jiang D, Selfridge J, et al.
J Clin Invest
. 2024 Jan;
134(5).
PMID: 38194275
Neutrophil extracellular traps (NETs), a web-like structure of cytosolic and granule proteins assembled on decondensed chromatin, kill pathogens and cause tissue damage in diseases. Whether NETs can kill cancer cells...
4.
Soulen M, Teitelbaum U, Mick R, Eads J, Mondschein J, Dagli M, et al.
Cardiovasc Intervent Radiol
. 2023 Dec;
47(1):60-68.
PMID: 38057498
Purpose: Capecitabine-Temozolomide (CapTem) is an oral chemotherapy regimen for NETs. Both drugs are radiosensitizers. Integrating CapTem and Y90 transarterial radioembolization (TARE) in patients with grade 2 neuroendocrine tumor (NET) liver...
5.
Alese O, Wu C, Chapin W, Ulanja M, Zheng-Lin B, Amankwah M, et al.
Am Soc Clin Oncol Educ Book
. 2023 May;
43:e389574.
PMID: 37155942
Colorectal cancer (CRC) is the third most common malignancy worldwide. It is projected to increase by 3.2 million new cases and account for 1.6 million deaths by 2040. Mortality is...
6.
Halfdanarson T, Strosberg J, Tang L, Bellizzi A, Bergsland E, ODorisio T, et al.
Pancreas
. 2020 Jul;
49(7):863-881.
PMID: 32675783
This article is the result of the North American Neuroendocrine Tumor Society consensus conference on the medical management of pancreatic neuroendocrine tumors from July 19 to 20, 2018. The guidelines...
7.
Shah M, Goldner W, Halfdanarson T, Bergsland E, Berlin J, Halperin D, et al.
J Natl Compr Canc Netw
. 2018 Jun;
16(6):693-702.
PMID: 29891520
The NCCN Guidelines for Neuroendocrine and Adrenal Tumors provide recommendations for the management of adult patients with neuroendocrine tumors (NETs), adrenal gland tumors, pheochromocytomas, and paragangliomas. Management of NETs relies...
8.
Russo S, Ammori J, Eads J, Dorth J
Future Oncol
. 2016 Feb;
12(5):669-85.
PMID: 26880384
Controversy remains regarding neoadjuvant approaches in the treatment of pancreatic cancer. Neoadjuvant therapy has several potential advantages over adjuvant therapy including earlier delivery of systemic treatment, in vivo assessment of...